CD8A and metastatic melanoma: After 3 weeks of mavorixafor monotherapy in patients with advanced metastatic melanoma, infiltration of the TME by CD8+ cells was suggested by increases in a majority of treated-patient CTL signature gene expression scores and IHC labeling of patient biopsy samples.